摘要
目的:观察沙利度胺(Thalidomide,反应停)联合奥沙利铂(L-OHP)、亚叶酸钙(CF)和氟尿嘧啶(5-FU)方案治疗晚期胃癌的临床疗效和患者的耐受性,并与单用后3种药物化疗进行比较。方法:采用随机分组的方法将45例晚期胃癌患者分为Thalidomide+L-OHP+CF+5-FU方案组(联合用药组)24例与L-OHP+CF+5-FU方案组(化疗组)21例,观察两组的临床疗效和患者的耐受性。结果:联合用药组有效率54.2%(13/24),化疗组有效率42.9%(9/21),联合用药组有效率高于化疗组,但两组差异无统计学意义(P>0.05)。联合用药组的疾病控制率为83.3%(20/24),化疗组为52.4%(11/21),两组差异有统计学意义(P<0.05)。联合用药组KPS评分的改善率为75%,化疗组KPS评分的改善率为42.9%,两组差异有统计学意义(P<0.05)。联合用药组的中位生存期及1年生存率均优于化疗组,但生存期比较差异无统计学意义(P>0.05)。联合用药组的恶心呕吐发生率较化疗组低,差异有统计学意义(P<0.05),但联合用药组的便秘的发生率较化疗组高,差异有统计学意义(P<0.05);其余毒副反应均相似。结论:与单用化疗相比,沙利度胺联合化疗方案能增加晚期胃癌患者的疾病控制率,同时改善患者的生活质量,具有较轻的消化道反应,疗效是否更优有待于进一步扩大样本量进行临床随机对照研究。
Objective：This study was designed to investigate the clinical curative effects and tolerance of patients with advanced gastric cancer of treatment with the regimen of thalidomide, oxaliplatin （ L-OHP）, leucovorin （CF） and fluorouracil （5-FU）. We compared this treatment with the regimen of oxaliplatin, leucovorin and fluorouracil. Methods：In a randomized manner,45 patients with advanced gastric cancer were divided into combined treatment group（thalidomide ＋ L-OHP ＋ CF ＋ 5-FU） and chemotherapy group （ L-OHP ＋ CF ＋ 5-FU）. We compared the clinical curative effects and tolerance between two groups. Results ： The overall responses rate for the combined treatment group and chemotherapy group were 54.2% （13/24） and 42.9% （9/21）, respectively. The overall responses to the combined treatment group were higher than that of the chemotherapy group, but there were no statistically significant difference between two groups （ P 〉 0. 05 ）. The clinically profitted rate from the combined treatment group and chemotherapy group were 83.3% （ 20/24 ） and 52. 4% （ 11/21 ）, respectively. There were statistically significant difference between two groups （ P 〈 0. 05 ）. The improvement rate of KPS score for the combined treatment group and chemotherapy group were 75% （18/24） and 42.9% （9/21）, respectively. Obviously, the improvement of life quality to the combined treatment group were higher than that of the chemotherapy group （P 〈0. 05）. The median survival and 1-year survival rate seen in the combined treatment group were better than that in the chemotherapy group, but there were no statistically significant difference between two groups （P 〉 0. 05 ）. Nausea and vomiting were more pronounced in the chemotherapy group （ P 〈 0. 05 ） ; Constipation was more pronounced in the combined treatment group （ P 〈 0.05 ） ; Other toxcities were similar. Conclusion ： Compared with chemotherapy regimen, thalidomide combined with chemotherapy reg imen obvi
出处
《临床肿瘤学杂志》
CAS
2008年第11期1012-1014,共3页
Chinese Clinical Oncology
关键词
晚期胃癌
沙利度胺
奥沙利铂
氟尿嘧啶
化学治疗
Advanced gastric cancer
Thalidomide
Oxaliplatin
Fluorouracil
Chemotherapy
